.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX27_Epcoritamab.Epcoritamab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX27_Epcoritamab.Epcoritamab| name: | Epcoritamab | |
| ATC code: | L01FX27 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 48 | mg |
| volume of distribution: | 3.67 | L |
| clearance: | 0.259 | L/day |
| other parameters in model implementation | ||
Epcoritamab is a bispecific CD3xCD20 T-cell–engaging antibody indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other CD20-positive B-cell malignancies. It is administered subcutaneously and is approved for clinical use in several regions.
Population PK analysis in patients with B-cell non-Hodgkin lymphoma (DLBCL, FL, MCL) following subcutaneous administration.
Li, T, et al., & Xu, S (2025). Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Clinical pharmacokinetics 64(1) 127–141. DOI:10.1007/s40262-024-01464-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39708278